On the immunoregulatory role of statins in multiple sclerosis: the effects on Th17 cells.
Georgios NtolkerasChrysanthi BarbaAthanasios MavropoulosGeorgios K VasileiadisEfthymios DardiotisLazaros I SakkasGeorgios HadjigeorgiouDimitrios Petros BogdanosPublished in: Immunologic research (2020)
Statins, the cholesterol-lowering drugs, also possess immunomodulatory properties, affecting among others T cell activation and differentiation, antigen presentation, and regulatory T cell (Tregs) maintenance and differentiation. Their effects on autoagression have led investigators to assess their clinical significance in autoimmune disease, such as multiple sclerosis (MS), a chronic progressive demyelinating disease of autoimmune nature. The dysregulated immunity noted in MS features a profound shift from Tregs dominance to Th17 cell superiority. In this review, we discuss the immunobiological basis of statins, their role in autoimmunity related to MS, and the data from experimental models and human studies on their effect on Th17 cells.
Keyphrases
- multiple sclerosis
- induced apoptosis
- cardiovascular disease
- white matter
- cell cycle arrest
- endothelial cells
- mass spectrometry
- endoplasmic reticulum stress
- cell therapy
- type diabetes
- oxidative stress
- mesenchymal stem cells
- single cell
- stem cells
- electronic health record
- cell proliferation
- machine learning
- artificial intelligence
- induced pluripotent stem cells
- case control
- pluripotent stem cells